BioLife Solutions - BLFS Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings or view top-rated stocks.

1 brokers have issued 12 month price objectives for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they predict the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts.

BioLife Solutions' stock was trading at $37.27 at the beginning of 2022. Since then, BLFS stock has decreased by 49.9% and is now trading at $18.67.
View the best growth stocks for 2022 here.

BioLife Solutions saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 16.1% from the October 31st total of 2,610,000 shares. Based on an average trading volume of 355,800 shares, the short-interest ratio is presently 8.5 days. Currently, 7.7% of the company's stock are sold short.
View BioLife Solutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our BLFS earnings forecast.

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to the consensus estimate of $31.65 million. BioLife Solutions had a negative net margin of 67.70% and a negative trailing twelve-month return on equity of 7.50%. During the same quarter in the previous year, the business earned ($0.02) EPS.

BioLife Solutions issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$164.00 million, compared to the consensus revenue estimate of $163.40 million.

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.66%), Vanguard Group Inc. (5.65%), Fred Alger Management LLC (5.06%), Geneva Capital Management LLC (3.61%), State Street Corp (2.88%) and Palisade Capital Management LLC NJ (2.16%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends.

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLFS stock can currently be purchased for approximately $18.67.

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $798.52 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

The company employs 432 workers across the globe.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.